ERCC1、TS在胃癌组织中的表达与术后辅助化疗预后的关系  

Relationship of the expression of ERCC1 and TS in gastric cancer tissue with the prognosis after postoperative adjuvant chemotherapy

作　　者：王维民[1] 周炎[1] 金俊[1] 姚强[1] 汤月华[1] 

机构地区：[1]江苏大学附属宜兴医院,江苏宜兴214200

出　　处：《现代中西医结合杂志》2015年第30期3307-3310,共4页Modern Journal of Integrated Traditional Chinese and Western Medicine

基　　金：无锡市科技局医疗与公众健康技术研发项目(CSE31N1333);江苏省恶性肿瘤生物标志物与防治重点实验室开放课题(11ZLKF09)

摘　　要：目的：探讨胃癌术后患者核苷酸切除修复交叉互补基因1（ERCC1）、胸苷酸合成酶（ TS）表达与术后辅助化疗预后的关系。方法选取86例初次诊断为胃癌行胃癌根治术、术后病理诊断为Ⅱ～Ⅲ期的患者，术后均采用XELOX辅助化疗方案化疗，并进行4年以上随访。运用免疫组化方法检测患者癌组织中ERCC1、 TS蛋白表达情况，分析ERCC1、TS表达与术后辅助化疗预后的关系。结果86例胃癌患者癌组织中ERCC1和TS的阳性表达率分别为40％和36％。 ERCC1和TS阳性表达率与肿瘤的分化程度相关。 ERCC1阴性表达者和TS阴性表达者平均生存期均明显长于阳性表达者（ P均＜0．05）。多因素COX回归分析表明，ERCC1、TS阳性表达者术后辅助化疗预后差[HR＝0．29，95％CI（0．12，0．69），P ＝0．006；HR＝0．49，95％CI（0．20，0．87），P＝0．010]。结论 ERCC1与TS表达情况可以作为预测胃癌术后辅助化疗预后的分子标志物。Objective It is to investigate the relationship of the expression of ERCC1 and TS in gastric cancer with the prognosis after postoperative adjuvant chemotherapy.Methods 86 patients who were diagnosed gastric cancer for the first time were enrolled in our study.All the patients were received radical operation, pathologic diagnosis stage wasⅡorⅢstage, and all accepted XELOX chemotherapy and followed at least 4 years.The expressions of ERCC1 and TS in gastric cancer tissue were detected by Immunohistochemistry method.The relationship of the expression of ERCC1 and TS with the prognosis was analyzed.Results The positive expression rate of ERCC1 and TS in 86 cases was 40%and 36%respectively.There were neg-ative correlation between the positive expression of ERCC1 and TS and the differentiation of tumor.The mean survival time of patients with negative expression of ERCC1 and TS were significant longer than those with positive expression （ all P〈0.05） . COX multivariate regression analysis revealed that patients with ERCC1 and TS didn＇t benefit from chemotherapy [HR=0.29, 95%CI（0.12,0.69）, P=0.006;HR=0.49, 95%CI（0.20, 0.87）, P=0.010].Conclusion ERCC1 and TS may be a biomarker to predict the prognosis of gastric cancer patients receiving chemotherapy.

关 键 词：胃癌 核苷酸切除修复交叉互补基因1 胸苷酸合成酶 辅助化疗 预后 ERCC1 

分 类 号：R735.2[医药卫生—肿瘤]